Vyant Bio Reports Third Quarter 2022 Results and Provides Strategic and Business Highlights
CHERRY HILL, N.J., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning to identify and validate drug targets and therapeutic candidates. Today, Vyant Bio announces results for the third quarter of 2022. The Company filed its Form 10-Q for the nine months ended September 30, 2022, with the Securities and Exchange Commission.
- Today, Vyant Bio announces results for the third quarter of 2022.
- The Company filed its Form 10-Q for the nine months ended September 30, 2022, with the Securities and Exchange Commission.
- I am pleased with Vyant Bios scientific progress in the third quarter of 2022, as we progress our repurposing compound toward a clinical trial in Q1 next year.
- On Wednesday, November 16, 2022 Vyant Bio will host an investor conference call and webcast at 4:30 pm ET.